close

Agreements

1 2 3 4 248
Number of results: 4945

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-10-15 Medivir (Sweden) nomination - restructuration Infectious diseases Restructuring
2018-10-15 Sarepta Therapeutics (USA - MA) Lysogene (France) LYS-SAF302 mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) licensing Rare diseases - Genetic diseases Licensing agreement
2018-10-15 Roche (Switzerland) SQZ Biotech (USA - MA) cell therapy platform, therapeutics derived from peripheral blood mononuclear cells (PBMCs) development - commercialisation Cancer - Oncology Development agreement
2018-10-10 Ionis Pharmaceuticals (USA - CA) Roche (Switzerland) IONIS-FB-LRx complement-mediated diseases including geographic atrophy development Ophtalmological diseases Development agreement
2018-10-10 Pierre Fabre (France) Embleema (USA - NY) Health Blockchain Consortium collaboration Technology - Services Collaboration agreement
2018-10-09 Ziopharm Oncology (USA - MA) Precigen (USA - MD) Sleeping Beauty licensing Cancer - Oncology Licensing agreement
2018-10-09 Iris Pharma (France) Keen Eye (France) artificial intelligence (AI) applications for bioimaging analysis ophtalmological diseases collaboration Ophtalmological diseases - Technology - Services Collaboration agreement
2018-10-09 ERS Genomics (Ireland) GenAhead Bio (Japan) CRISPR/Cas9 genome editing technology patents licensing Technology - Services Licensing agreement
2018-10-09 UniCAR-Therapy Bio-Medicine Technology (China) Terumo BCT (USA - CO) cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies collaboration Technology - Services - Cancer - Oncology Collaboration agreement
2018-10-08 Cytosen Therapeutics (USA - TX) member of the board of directors nomination Cancer - Oncology Nomination
2018-10-08 Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) manufacturing platform for gene therapy programs manufacturing - bioproduction Rare diseases - Genetic diseases - Technology - Services Production agreement
2018-10-08 eTheRNA immunotherapies (Belgium) mRNA manufacturing facility opening of new premises Cancer - Oncology - Technology - Services Opening of new premises
2018-10-08 Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company lentivirus cancers, undisclosed rare disease services contract Technology - Services Services contract
2018-10-05 Oxford Biomedica (UK) Orchard Therapeutics (UK) lentiviral vectors for ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders adenosine deaminase severe combined immunodeficiency (ADA-SCID), mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A), undisclosed follow-on indications. collaboration Rare diseases - Genetic diseases Licensing agreement
2018-10-05 Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) AAV1 neurotrophin 3 (NT-3) gene therapy Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A licensing Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement
2018-10-04 Arrowhead Pharmaceuticals (USA - CA) Janssen Pharmaceutical, a J&J Company (USA)
  • ARO-HBV and up to three additional RNA interference (RNAi) therapeutics
hepatitis B licensing - research Infectious diseases Licensing agreement
2018-10-04 Horizon Discovery (UK) Celyad (Belgium) shRNA technology licensing Technology - Services Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) Novartis (Switzerland) LYS228, IID572, MAK181 carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections licensing Infectious diseases Licensing agreement
2018-10-03 Boston Pharmaceuticals (USA - MA) GSK (UK) GSK3352589, GSK3008356, GSK3183475 and two undisclosed preclinical programs acne, irritable bowel syndrome with diarrhea (IBS-D) licensing Autoimmune diseases - Dermatological diseases - Digestive Diseases - Inflammatory diseases Licensing agreement
2018-10-03 Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA) combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor licensing Cancer - Oncology Licensing agreement